JAK3 and cancer: Therefore, based on the relationship between the IL4/IL13, IL4R receptor complex, and JAK1/JAK2/JAK3-STAT6, there have been multiple clinical trials to treat human cancers via inhibition or blocking of the IL4Rα/IL13Rα1 pathway [1–3].